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In vitro fermentation of gum acacia - impact on the faecal microbiota 23 
Abstract  24 
Interest in the consumption of gum acacia (GA) has been associated with beneficial health 25 
effects, which may be mediated in part by prebiotic activity. Two doses of GA and 26 
fructooligosaccharide (FOS) (1% and 2%) were tested for their efficacy over 48 h in pH- and 27 
temperature-controlled anaerobic batch cultures inoculated with human faeces. Samples were 28 
taken after 0, 5, 10, 24, and 48 h of fermentation. The selective effects of GA (increases in 29 
Bifidobacterium sp. and Lactobacillus sp.) were similar to those of the known prebiotic FOS. 30 
The 1% dose of substrates showed more enhanced selectivity compared to the 2% dose. The 31 
fermentation of GA also led to SCFA production, specifically increased acetate after 10, 24, 32 
and 48 h of fermentation, propionate after 48 h, and butyrate after 24 and 48 h. Additionally, 33 
FOS led to significant increases in the main SCFAs. These results suggest that GA displays 34 
potential prebiotic properties.  35 
Key words  36 
Gum acacia (GA); Prebioitcs; Intestinal bacteria; In vitro fermentation.  37 
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Introduction  50 
The colon has the most abundant and diverse population of bacteria in the human body and is 51 
inhabited by around 1000 different bacterial species, which can reach 1014 colony-forming 52 
units  CFU (Gibson and Roberfroid 1995). The human microbiome is a complex and dynamic 53 
system that plays an important role in human health (Eckburg et al. 2005, Kaiko and 54 
Stappenbeck 2014). By interacting with consumed material, colonic inhabitants ferment 55 
undigested food and secrete end products such as gases and SCFA (Gibson and Roberfroid 56 
1995). Moreover, the composition of the bacterial population may shift, resulting in increases 57 
in bacteria associated with beneficial effects. Inulin and FOS are known prebiotics that are 58 
commercially used worldwide (Mandalari et al. 2008, Steer et al. 2003). A prebiotic is 59 
defined as “a selectively fermented ingredient that results in specific changes in the 60 
composition and/or activity of the gastrointestinal microbiota, thus conferring benefit(s) upon 61 
host health” (Gibson et al. 2010).  62 
GA is derived from acacia trees of the Leguminosae family. It is an arabinogalactan protein 63 
complex with an approximate molecular weight of 350-850 K Da (Mahenran.T et al. 2008,, 64 
Williams and Phillips 2000. ). It is a polysaccharide consisting of branched chains of (1-3) 65 
linked β-D galactopyranosyl units. Side chains, 2 to 5 units in length, are attached by (1-6) 66 
units to the main chain. Both the main and side chains contain α-L-arabinofuranosyl, α-L-67 
rhamnopyranosyl, β-D-glucuronopyranosyl, and 4-O-methyl-β-D-glucuronopyranosyl units 68 
(Bliss et al. 2013). GA is widely used in the pharmaceutical and food industries as an additive 69 
, a stabilising, thickening, and an emulsifying agent (Dauqan and Abdullah 2013) (Verbeken 70 
et al. 2003).  71 
GA is not digestible in the small intestine and is fermented in the large intestine, and has been 72 
observed to lead to increases in Bifidobacterium spp.  (Calame et al. 2008) (Terpend et al. 73 
2013) (Marzorati et al. 2015). Bifidobacterium spp. have been shown to inhibit the growth of 74 
 
 
4 
pathogenic bacteria, modulate the immune system, and produce SCFAs, which reduce the pH 75 
in the colon, imparting antimicrobial activity against pathogens (Gibson and Roberfroid 76 
1995). A variety of GA doses ranging from 5 to 40 g/d have been reported to be effective in 77 
increasing Bifidobacterium spp.  and Lactobacillus spp. populations (Calame, Weseler, 78 
Viebke, Flynn and Siemensma 2008, Cherbut et al. 2003). These lines of evidence indicate 79 
that GA has bifidogenic potential in healthy humans. However optimal effective doses have 80 
not been defined. The results from most previous studies cannot be directly compared, as 81 
different methodologies, population groups, and types of GA have been studied. In addition, 82 
high daily doses of GA could result in the manifestation of adverse effects such as mild 83 
diarrhoea and bloating (Babiker et al. 2012).  84 
 85 
In vitro batch culture systems are used to simulate the main physiological and 86 
microbiological processes in the distal colon and can be combined with metabolic and 87 
molecular analyses. Therefore, the aim of the following study was to investigateof the impact 88 
of two GA doses on the faecal microbiota following 48 h  fermentation in pH-controlled 89 
batch culture systems, as compared to the known prebiotic  FOS.  90 
 91 
Material and methods  92 
Substrates 93 
GA (KLTA-MF-Kerry Ingredients, U.K.) was in spray dried form as a water soluble, free-94 
flowing powder (food-grade). Table (1) shows the composition of GA used in this study, 95 
dietary fibre were analysed by Campden BRI Laboratories (AOAC method 991·43). The 96 
FOS used was Orafti® P95 (Beneo, Belgium) extracted from chicory root.  97 
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[Table 1 near here]. 98 
 99 
In vitro Upper Gut Digestion  100 
Upper gut digestion was performed according to the protocol of Mills et al.(2008) (Mills et 101 
al. 2008). Briefly,  60 g of GA powder was added to 150 ml of distilled water and the solution 102 
mixed with  20 mg α–amylase in 6.25 ml CaCl₂ (1 mM) and incubated on a shaker at 37 °C  103 
for 30 minutes. This simulated the initial oral digestion. Subsequently, 2.7 g of pepsin in 104 
25ml of HCl (0.1M) was used to facilitate gastric breakdown of the sample. The pH was then 105 
reduced progressively to 2 by adding 6 M HCl, before incubating on a shaker at 37°C for 2 106 
hours. A further 560mg of pancreatin and 3.5g of bile, in 125 ml of  NaHCO₃ solution, was 107 
added to simulate the effect of the small intestine on the gum sample. The pH was increased 108 
to 7 by adding NaOH (6M) and the resulting suspension incubated on a shaker at 37°C for 3 109 
hours. Samples were transferred to cellulose dialysis membrane (1 KDa molecular weight), 110 
purchased from Cheshire biotech Cheshire, UK, and dialysed against 10Mm of NaCl solution 111 
at 5°C to remove low molecular mass digestion products. After 15 hours, the dialysis fluid 112 
was changed and dialysis continued for additional 2 h. The sample within the dialysis tubing 113 
was freeze dried (5 days) prior to use in batch culture systems. The final sample was weighed 114 
and GA loss in the upper gut was subsequently calculated. 115 
Faecal sample preparation  116 
Faecal samples were obtained from three healthy volunteers (31- 35 years of age), who had 117 
not been consuming antibiotics for at least 6 months before the study and had no history of 118 
gastrointestinal disease. Volunteers were not consumers of probiotic or prebiotic 119 
supplements. Samples were prepared on the day of the experiment and within 1 hour of 120 
production and were diluted to 1:10, w/v in anaerobic phosphate buffer (0.1 M; pH7.4). 121 
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Samples were homogenised in a stomacher for 2 min, the resulting slurry was inoculated into 122 
batch culture fermenters.  123 
Batch cultures  124 
Three independent batch culture experiments were carried out using faeces from a different 125 
donor each time. Vessels were autoclaved and then aseptically filled with 135 ml of basal 126 
medium (peptone water (2 g/l), yeast extract (2 g/l), NaCl (0.1 g/l), K2HPO4 (0.04 g/l), 127 
KH2PO4 (0.04 g/l), NaHCO3 (2 g/l), MgSO4•7H2O (0.01 g/l), CaCl2•6H2O (0.01 g/l), tween 128 
80 (2 ml/l), hemin (50 mg/l), vitamin K1 (10 ml/l), L-cysteine (0.5 g/l), bile salts (0.5 g/l), 0.5 129 
ml/l of 10% cysteine –HCl, resazurin (1 mg/l)). Vessels were left overnight with nitrogen 130 
pumping (15mL/min) through the vessel to provide an anaerobic environment. Before 131 
addition of faecal slurry, temperature of basal medium was set at 37 °C and pH was 132 
maintained at 6.7-6.9 using a pH meters (Electrolab pH controller, Tewksbury, UK) by the 133 
addition of 0.5 M HCl or 0.5M NaOH. The vessels were stirred using magnetic stirrers. 1.5g, 134 
3g (1% w/v) of FOS and 0.6 g and 0.3 g (1:10 w/v) of pre-digested GA (taking to account the 135 
loss of substrate in the upper gut from the predigestion) were added to the vessel 1% and 136 
doubling the dose 2% just prior to the addition of 15 ml of faecal slurry (10%w/w). The 137 
vessels were left for 48h, with samples taken at 0, 5, 10, 24 and 48h. Samples were 138 
centrifuged in preparation for GC analysis, or prepared for microbial enumeration by FISH.  139 
Florescence in situ hybridisation (FISH) analysis 140 
To asses diffrences in bacterial population,  samples hybridised as described by Daims et al., 141 
1999 (Daims et al. 1999). A sample of 375-µl obtained from each vessel was fixed for four 142 
hours 4˚C in 1125 μ L (4% w/v) paraformaldehyde. Fixed samples were then centrifuged at 143 
11,337g (Eppendorf centrifuge minispin, Eppendorf, UK) at room temperature for 5 minutes. 144 
The supernatant removed and discarded. The pellet was resuspended in 1 ml of cold 1×PBS 145 
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by aspirating carefully using a pipette. This step was conducted twice. The washed cells were 146 
suspended in 150 µL of cold 1×PBS, then 150 µL of ethanol (99%) was added and the 147 
samples were stored at -20˚C.  148 
The oligonucleotide probes used were commercially synthesised and labeled with the 149 
fluorescent dye Cy3 (Sigma Aldrich Co. Ltd. UK). These were: Bif164 for Bifidobacterium 150 
spp. (BIF), Lab158 for Lactobacillus/enterococcus (LAB), Ato291 for Atopobium cluster 151 
(Atopobium, Coriobacterium, Collinsella spp.) (ATO), Chis 150 for Clostridium histolyticum 152 
group (CHIS) Erec 482 for  Eubacterium rectale – Clostridium coccoides group  (EREC), 153 
Bac 303 for  Bacteroides–Prevotella group (BAC). EUB 338 mixture consisting of EUB338, 154 
EUB338II and EUB338III for total bacteria (Total) see Table (2). For the hybridisation 20 μ 155 
L of diluted sample was pipetted onto a teflon poly-L-lysine-coated six-well slide (Tekdon 156 
Inc., Myakka City, FL). The samples were dried onto the slides at 46-50˚C for 15 minutes 157 
and after that dehydrated in an alcohol series 50, 80, and 96%. The ethanol was allowed to 158 
evaporate from the slides before hybridisation buffer was added. A probe/hybridization buffer 159 
mixture (5 μL of a 50 ng/μL stock of probe plus 50 μL of hybridization buffer). To 160 
permeabilise the cells for use with probes Bif164 and Lab158, samples were treated with 20 μ 161 
L of lysozyme at room temperature for 15 min before being washed briefly for 2−3 seconds 162 
in water and then dehydrated in the ethanol series. Then slides were placed in hybridisation 163 
oven for 4 hours (ISO 20 oven, Grant Boekel). For the washing step, slides were placed in 50 164 
ml of washing buffer (0.9 M NaCl, 0.02 M Tris/HCl (pH 8.0), 0.005 M 165 
ethylenediaminetetraacetic acid (EDTA) solution (pH 8.0, Table (2), warmed at the 166 
appropriate temperature for each probe and 20 μL of 4;6-diamidino-2-phenylindole di 167 
hydrochloride (DAPI) was added to the washing buffer for 15 min. They were then briefly 168 
washed (2−3 s) in ice-cold water and dried under a stream of compressed air. Five microliters 169 
of ProLong Gold antifade reagent (Invitrogen) was added to each well and a coverslip 170 
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applied. Slides were stored in the dark at 4 °C until cells were counted under a Nikon E400 171 
Eclipse microscope. DAPI stained cells were examined under UV light, and a DM510 light 172 
filter was used to count specific bacteria hybridised with the probes. For each slide, 15 173 
random different fields of view were counted. 174 
[Table 2 near here]. 175 
Preparation sample for short chain fatty acids  176 
Samples were extracted and derivatised as previously described (Richardson et al. 1989). 177 
Samples were defrosted and 1ml of each sample or standard solution was transferred into a 178 
labeled 100 mm × 16mm glass tube with the internal standard of 50µl of 2- ethyl butyric acid 179 
(0.1M). 0.5 ml concentrated HCl and 2 ml of diethyl ether was added to each glass tube and 180 
samples vortexed for 1 min. samples were centrifuged at 2000 g for 10 min (SANYO MSE 181 
Mistral 3000i; Sanyo Gallenkap PLC, Middlesex, UK). The diethyl ether (the upper layer) 182 
was transferred in a new glass tube. A second extraction was conducted by adding 1 ml of 183 
diethyl either to the sample followed by vortex and centrifugation. 400 µl of pooled ether 184 
extract and 50 µl N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) was 185 
added in a GC screw-cap vial. Samples were heated at 80°C for 20 minutes and then left at 186 
room temperature for 48 hours to allow lactic acid in the samples to completely derivatise.  187 
A 5890 SERIES II Gas Chromatograph (Hewlett Packard, UK) using an Rtx-1 10m×0.18mm 188 
column with a 0.20μm coating (Crossbond 100% dimethyl polysiloxane; Restek, 189 
Buckinghamshire, UK) was used for analysis of SCFA. Temperatures of injector and detector 190 
were 275°C, with the column programmed from 63°C for 3 minutes to 190°C at 10°C min-1 191 
and held at 190°C for 3 minutes. Helium was the carrier gas (flow rate 1.2 ml min-1; head 192 
pressure 90 MPa). A split ratio of 100:1 was used.  The standard solution contained (mM): 193 
sodium formate, 10; acetic acid, 30; propionic acid, 20; isobutyric acid, 5; n-butyric acid, 20; 194 
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iso-valeric acid, 5; n-valeric acid, 5; sodium lactate, 10; sodium succinate, 20. The sample 195 
was injected onto the column, which was maintained at 140 oC for the first 5 minutes, 196 
temperature of the column was increased over 5 minutes to 240 oC. To maintain appropriate 197 
calibration after injection of every 20 samples an external standard solution, with known 198 
concentrations of SCFAs was injected. Peaks and response factors within samples were 199 
calibrated and calculated using ChemStation B.03.01 software (Agilent Technologies, 200 
Cheshire, UK).  201 
Statistical analysis  202 
GA and FOS both doses were tested in batch cultures inouculated with faecal samples 203 
collected from three individial donors in three separate experiments. The log 10 numbers of 204 
specific bacteria were expressed as mean values and standard diviation. Statistical tests were 205 
performed using SPSS, (SPSS Statistical Software, Inc., Chicago, IL, USA), version 18.0 A 206 
repeated measures one-way analysis of variance ANOVA to test the effect of time with the 207 
factor subjects, with five levels (0 h, 5 h, 10 h, 24 h and 48 h) and to assess the significant 208 
differences between the two subjects in the same time points. Significant differences between 209 
times point were represented by “*” p <0.05, “**” p<0.01 and “***” p < 0.001. 210 
Results  211 
Effects of different doses of GA and FOS on human faecal bacteria 212 
To assess the impact of GA on the intestinal microbiota composition, pH-controlled, 213 
anaerobic, faecal batch cultures were conducted using FOS as a positive prebiotic control. 214 
Samples were taken after 0, 5, 10, 24, and 48 h of fermentation. Bacteria were enumerated by 215 
FISH.  216 
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The fermentation of GA at the 1% dose led to increased numbers of Bifidobacterium spp. 217 
after 5, 10, and 24 h of fermentation and of Lactobacillus spp. after 5 and 24 h compared with 218 
the levels at 0 h, as shown in Tables (3a, 3b). However, a small but statistically significant 219 
drop in Bifidobacterium spp. compared with the negative control was seen after 24 h 220 
(7.53±0.10, 7.22±0.37 GA 1%) ( 7.46±0.21, 7.64±0.29 control). 221 
Fermentation of 2% GA a led to a significant increase in Bifidobacterium spp. after 5 and 10 222 
h compared with the baseline levels (time 0 h). Total bacteria increased after the fermentation 223 
of 2% GA for 48 h compared with the baseline levels.  224 
The 1% dose of FOS led to a significant increase in Bifidobacterium spp. after 5 h compared 225 
with baseline (7.39± 0.21, 7.83± 0.06). Lactobacillus spp. increased following fermentation 226 
of FOS at a dose of 1% at 5, 10, and 24 h. The 2% FOS dose significantly increased 227 
Bifidobacterium spp. numbers after 24 h compared with the negative control (8.12±0.16, 228 
7.78±0.17) and after 5 h compared with baseline levels (p = 0.03), whereas an increase in 229 
Lactobacillus spp. was observed after 5 h (7.75±0.14, 7.29± 0.07)  and 24 h (7.51± 0.10, 230 
7.29± 04) (p = 0.01 and 0.02, respectively) compared with the negative control.  231 
The number of bacteria in the C. histolyticum group decreased after fermentation of 1% FOS 232 
and 1% GA for 5 and 10 h, respectively, compared with the baseline levels. Additionally, GA 233 
and FOS enhanced the growth of Atopobium spp. after 5 h of fermentation compared with the 234 
baseline levels. The C. coccoides-Eubacterium rectale group did not change with any of the 235 
tested substrates. Additionally, Atopobium also increased after 5 h of fermentation of 2% 236 
FOS.  237 
In the current study both substrates led to increases in Bacteroides spp.; these changes 238 
occurred after 5 h of fermentation of GA and FOS at the 1% dose (p = 0.01 and p = 0.02, 239 
respectively) and with the 2% dose of GA and FOS compared with the baseline levels (p = 240 
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0.02 and p = 0.00, respectively). Moreover, 1% FOS increased Bacteroides spp. after 24 h (p 241 
= 0.01). On the other hand, the prebiotic FOS at the 1% dose enhanced the growth of total 242 
bacteria, achieving statistical significance after 10 h and 24 h. Additionally, total bacterial 243 
growth was enhanced with 2% FOS after 5 h compared with the negative control.  244 
[Tables 3a & 3b near here]. 245 
Impact of GA and FOS on SCFA production 246 
Table (4) shows that within 1% GA, the concentration of acetate significantly increased after 247 
24 h of fermentation (p ≤ 0.05) and exhibited an increasing trend after 5, 10, and 48 h (p = 248 
0.06, 0.06, and 0.08, respectively). Acetate levels were elevated at all time points after FOS 249 
fermentation compared with the levels at 0 h (p = 0.00, 0.00, 0.04, and 0.00, respectively), 250 
and 1% FOS led to an increase after 5 h compared with the negative control (p = 0.01). 251 
Butyrate production was significantly enhanced following the fermentation of FOS between 0 252 
and 24 h (p = 0.02) and following GA 1% fermentation after 24 and 48 h (p = 0.03, 0.02); 253 
this was also the case at 24 h when compared with the negative control (p = 0.04). Compared 254 
with the levels at 0 h, propionate production increased following the fermentation of GA1% 255 
for 48 h (p = 0.03) and the fermentation of 1% FOS for 24 h (p = 0.01). 256 
Additionally, with 2% FOS, acetate increased after 24 and 48 h (p = 0.00 and 0.01, 257 
respectively), and with 2% GA, acetate increased after 48 h compared with the baseline levels 258 
(p = 0.02). Butyrate production increased following the fermentation of 2% GA for 10 and 48 259 
h compared with the levels at 0 h (p= 0.01 and 0.03, respectively). In addition, propionate 260 
increased after 10 h of fermentation of 2% FOS compared with the negative control (p = 261 
0.04) and the baseline values (p = 0.01).  262 
[Table 4 near here]. 263 
* 
* 
* 
 
 
12 
Discussion  264 
Prior studies have noted the importance of the effect of GA on improving human health 265 
(Terpend, Possemiers, Daguet and Marzorati 2013). GA is not digestible in the upper 266 
gastrointestinal tract, therefore it can reach the large intestine where it is fermented by 267 
intestinal bacteria (Adiotomre et al. 1990),(Annison et al. 1995), (Bourquin et al. 1996). 268 
Therefore this study aimed to determine the effects two doses of GA on human intestinal 269 
bacteria and to assess prebiotic potential as compared to prebiotic FOS. As such pH-270 
controlled batch culture fermentation systems were used to evaluate the selectivity of GA 271 
when fermented with healthy human gut microbiota compared with FOS at two different 272 
doses.  273 
Several studies have shown that GA can undergo a slow fermentation, specifically a more 274 
distal fermentation, whereas existing prebiotics typically undergo proximal fermentation 275 
(Macfarlane et al. 1992), as proteolytic fermentation develops in the distal colon; therefore, 276 
this substrate may be able to be saccharolytically fermented in this part of colon. In this 277 
present study GA fermentation shows selectivity in bifidobacteria and Lactobacillus spp at 278 
time 10 h and continues to 24 h which could indicate slower fermentaion and is inline with 279 
others work (Cherbut, Michel1, Raison1, Kravtchenko and Severine 2003). However, it is 280 
worth noting that the bifidogenic effect of the 1% was not maintained at 48 hours in current 281 
study. 282 
In the present study, GA significantly enhanced the growth of Bifidobacterium spp.. 283 
Bifidobacterium is considered an important group related to human health, having a 284 
favourable impact in the large intestine (Gibson and Wang 1994),(Russell et al. 2011). These 285 
results are consistent with those of Calame et al (2008) in which the consumption of 10 g of 286 
GA daily by healthy adults had a beneficial effect on the gut microbial composition, and 287 
increases in bifidobacteria (Calame, Weseler, Viebke, Flynn and Siemensma 2008). 288 
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Furthermore, the 1% dose also led to increases in lactobacilli. Lactobacilli has long been 289 
considered a positive microbial group; as such, stimulation of this genera offers potential 290 
benefits to the host (Ouwehand et al. 2009). The 2% dose did not lead to the same lactobacilli 291 
impact. The use of a higher doasge could have impacted on selectivity through a cross 292 
feeding network (Guiot 1982). 293 
Furthermore, after 10 h, the numbers of bacteria in the C. histolyticum group decreased 294 
following the fermentation of  1% GA, which also agreed with results of in vivo studies 295 
(Wyatt et al. 1986), (Calame, Weseler, Viebke, Flynn and Siemensma 2008), (Cherbut, 296 
Michel1, Raison1, Kravtchenko and Severine 2003). This group of bacteria has sometimes 297 
been associated with inflammation and large bowel disease (Hughes 2008), (Gibson and 298 
Roberfroid 2008). It is thought that increased numbers of beneficial bacteria could lower the 299 
pH within the colon, therefore making the environment unfavourable for pathogenic groups; 300 
the results of the present study indicate that the fermentation of GA selectively increased the 301 
number of beneficial bacteria and reduced the number of harmful bacteria. This result further 302 
suggests the lower dose to offer improved selective potential. 303 
In the current study GA fermentation resulted in a similar bacterial profile to FOS. Several 304 
in vivo and in vitro studies have confirmed that FOS can regulate the gut through the selective 305 
stimulation of the gut microbiota (Hidalgo et al. 2012), (Palframan et al. 2002), (Cueva et al. 306 
2013), (Tuohy et al. 2001), therefore, GA could has potentially prebiotic properties. GA can 307 
be incorporated into baked goods, therefore could provide an alternative prebiotic source for 308 
inclusion in the diet. 309 
Moreover, an increase in Bacteroides spp. was observed with in GA and FOS,  this group is 310 
associated with a range of colonic activities (Pool-Zobel et al. 2002), (Nakamura et al. 2002). 311 
Bacteroides spp. constitute a large proportion of the microbial population in the healthy adult 312 
gastrointestinal tract (Walton 2006). In previous in vivo and in vitro studies on GA 313 
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fermentation, increased propionate levels were associated with Bacteroides spp. and 314 
Prevotella spp. which has relevance to the improving in lipid metabolism (Frost et al. 315 
2014),(Tulung et al. 1987).  316 
The results show that both doses of GA were selectivly fermented. The higher dose was 317 
arguably less selective as the impact on lactobacilli and C. histolyticum groups were no 318 
longer apparent. In fact Calame et al (2008) noted that an increase in the concentration of 319 
substrates results in less selectivity (Calame, Weseler, Viebke, Flynn and Siemensma 2008). 320 
This might be explained by competiton for substrate, at higher dose other bacterial strains 321 
have easier access to the substrate and subsequently, become less selevtively than the lower 322 
dose.  323 
GA fermentation induced modulation of the colonic microbiota, with increased levels of 324 
acetate, propionate, and butyrate. Acetate is produced mainly through the fructose-6-325 
phosphate phosphoketolase pathway by bifidobacteria, and the increased production of this 326 
acid could be related to increased numbers of this group (Miller and Wolin 1996). Acetate 327 
plays an important role in controlling inflammation and resisting invasion by pathogens 328 
(Rigottier-Gois et al. 2003). Propionate may be produced by Cluster IX Clostridia groups; 329 
indeed an increase in this bacterial groups was observed during GA fermentation Hosseini et 330 
al (2011). Propionate may have a direct role in central appetite regulation; increasing satiety 331 
and reducing food intake by the host (Russell et al. 2013), (Brown et al. 2003), (Chambers et 332 
al. 2015), (Cherbut et al. 1998). Whilst butyrate is often used as an energy source by 333 
epithelial cells; as such . these SCFA increases could offer benefits to the host. 334 
The pH-controlled stirred batch culture systems enabled rapid analysis of the effects of 335 
GA on the faecal microbiota. In the absence of absorption, colonic secretions, and epithelial 336 
interactions, the system has limitations. However, processes such as SCFA production can 337 
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still be monitored away from the impact of additionally dietary factors. Thus, batch culture 338 
systems provide an alternative way of assessing how bacteria ferment a substrate and the end 339 
products they produce (Ohashi et al. 2012).  340 
The comparisons of the substrates in the pH-controlled batch cultures indicated that GA 341 
has selective abilities that are at least similar to those of the known prebiotic FOS, as 342 
indicated by the bacteriology results and increased concentrations of acetate, butyrate, and 343 
propionate. These results could be relevant to improving host health by increasing the levels 344 
of the bifidobacteria group, especially in individuals with lower numbers such as elderly 345 
population. Tuohy et al (2001) reported that prebiotics can alter the gut microbiota in those 346 
with initially low numbers of bifidobacteria (Tuohy, Kolida, Lustenberger and Gibson 2001). 347 
This may be particularly relevant in elderly people. Elderly are experiencing negative 348 
changes in their gut microbiota.  349 
Conclusion  350 
The aim of the current study was to use in vitro batch cultures to assess the effects of GA on 351 
the microbiota compared to FOS. Here, we showed that GA modulated the gut microbiota 352 
similarly to FOS, furthermore, the 1% dose showed additional selective potential. As such 353 
GA holds the potential to be used as a novel prebiotic source. 354 
 355 
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Table 1: Composition and nutritional profile of GA used in the present study 591 
 592 
Analysis Results 
Energy (kcal) 1205kJ/100g 
Protein 2.1g/100g 
Total carbohydrate (by difference) 82.6g/100g 
Carbohydrate (avail) 56.5g/100g 
Total Suger* 0.6g/100g 
Fibre 26.1g/100g 
Fat 0.1g/100g 
Sodium 11.0mg/100g 
Moisture 11.8g/100g 
Ash 3.49g/100g 
 
 
22 
* Total sugars are the sum of glucose, sucrose and fructose expressed as monosaccharides 593 
 594 
 595 
 596 
 597 
 598 
 599 
 600 
 601 
 602 
 603 
 604 
 605 
 606 
 607 
 608 
Table 2 : Hybridisation and washing conditions for oligonucleotide probes 609 
Probe 
name 
Sequence (5’ to 3’) 
Hybridisation 
pre-treatment 
Formamid
e (%) in 
hybridisat
ion buffer 
Hybridisati
on 
temperature 
(°C) 
Washing 
temperatur
e (°C) 
Reference 
Ato 291 GGTCGGTCTCTCAACCC Lysozyme 0 50 50 
(Harmsen et 
al. 2000) 
Lab 158 GGTATTAGCAYCTGTTTCCA Lysozyme 0 50 50 
(Harmsen et 
al. 1999) 
Bif 164 CATCCGGCATTACCACCC Lysozyme 0 50 50 
(Langendijk 
et al. 1995) 
Erec 482 GCTTCTTAGTCARGTACCG None 0 50 50 
(Franks et 
al. 1998) 
Chis 150 TTATGCGGTATTAATCTYCCTTT None 0 50 50 
(Franks, 
Harmsen, 
Raangs, 
Jansen, 
Schut and 
Welling 
1998) 
 
 
23 
 610 
 611 
 612 
 613 
Bac 303 CCAATGTGGGGGACCTT None 0 46 48 
(Manz et al. 
(1996)) 
EUB338* GCTGCCTCCCGTAGGAGT None 35 46 48 
(Daims, 
Brühl, 
Amann, 
Schleifer 
and Wagner 
1999) 
EUB338II* GCAGCCACCCGTAGGTGT None 35 46 48 
(Daims, 
Brühl, 
Amann, 
Schleifer 
and Wagner 
1999) 
EUB338III
* 
GCTGCCACCCGTAGGTGT None 35 46 48 
(Daims, 
Brühl, 
Amann, 
Schleifer 
and Wagner 
1999) 
* These probes are used together in equimolar concentrations (all at 50 ng l1) 
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 Bif164 Lab158 Ato291 Bac303 Erec482 Chis150 EubI-II-III 
 mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
Control 0h 7.46 0.21 7.24 0.09 7.40 0.18 7.85 0.24 7.96 0.20 6.91 0.24 8.26 0.35 
Control 5h 7.76 0.20 7.29 0.07 7.60 0.15 8.04 0.20 7.36 0.07 6.42 0.38 8.45 0.08 
Control 10h 7.75 0.24 7.47 0.07 7.56 0.02 8.25 0.28 7.51 0.07 6.99 0.16 8.44 0.04 
Control 24h 7.78 0.16 7.29 0.04 7.54 0.14 8.12 0.21 7.54 0.08 5.73 0.47 8.53 0.36 
Control 48h 7.64 0.29 7.14 0.50 7.50 0.61 7.76 0.17 7.51 0.06 5.68 0.73 8.42 0.18 
FOS 0h 7.39 0.21 7.31 0.08 7.52 0.09 7.80 0.11 7.72 0.2 6.62 0.53 8.21 0.14 
FOS 5h 7.83 * 0.06 7.78  ** 0.04 7.83  * 0.10 8.16  * 0.09 7.41 0.16 5.71  * 0.55 8.78  0.11 
FOS 10h 8.00 0.07 7.53  ** 0.09 7.77 0.30 8.30 0.10 7.83 0.29 6.23 1.09 8.72 * 0.08 
FOS 24h 8.17 0.23 7.75 * 0.14 7.79 0.31 8.24  * 0.01 7.50 0.12 6.27 0.88 8.83 * 0.14 
FOS 48h 7.82 0.15 7.44 0.15 7.58 0.18 7.93 0.18 7.28 0.19 5.65 0.69 8.57 0.17 
GUM 0h 7.53 0.10 7.00 0.16 7.43 0.05 7.70 0.22 7.81 0.37 6.08 0.50 8.29 0.22 
GUM 5h 7.92  * 0.11    7.32  * 0.05 7.80 ** 0.06 7.97 * 0.19 7.42 0.11 6.64 0.42 8.54 0.18 
GUM 10h 7.90  * 0.14    7.46 0.11 7.60 0.26 8.01 0.35 7.44 0.166 5.87  * 0.82 8.79 0.71 
GUM 24h 7.93  * 0.06    7.59  ** 0.22 7.66 0.22 8.08 0.52 7.65 0.17 5.87 0.82 8.53 0.25 
GUM 48h 7.22  a 0.37 7.39 0.11 7.53 0.40 8.20 0.24 7.39 0.49 6.28 0.86 8.49  0.56 
B 
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 617 
 Bif164 Lab158 Ato291 Bac303 Erec482 Chis150 EubI-II-III 
 mean SD mean SD mean SD mean SD mean SD mean SD mean SD 
Control 0h 
Control 5h 
Control 10h 
Control 24h 
Control 48h 
7.46 
7.76 
7.75 
7.78 
7.64 
0.21 
0.20 
0.24 
0.16 
0.29 
7.24 
7.29 
7.47 
7.29 
7.14 
0.09 
0.07 
0.07 
0.04 
0.50 
7.40 
7.60 
7.56 
7.54 
7.50 
0.18 
0.15 
0.02 
0.14 
0.61 
7.85 
8.04 
8.25 
8.12 
7.76 
0.24 
0.20 
0.28 
0.21 
0.17 
7.96 
7.36 
7.51 
7.54 
7.51 
0.20 
0.07 
0.07 
0.08 
0.06 
6.91 
6.42 
6.99 
5.73 
5.68 
0.24 
0.38 
0.16 
0.47 
0.73 
8.26 
8.45 
8.44 
8.53 
8.42 
0.35 
0.08 
0.04 
0.36 
0.18 
FOS 0h 
FOS 5h 
FOS 10h 
FOS 24h 
FOS 48h 
7.4 
7.93 * 
8.02 
8.12  a 
7.88 
0.1 
0.15 
0.11 
0.17 
0.11 
7.24 
7.75  a 
7.58 
7.51 a 
7.43 
0.24 
0.14 
0.14 
0.1 
0.15 
7.57 
7.98 ** 
7.89 
7.81 
7.67 
0.10 
0.12 
0.18 
0.19 
0.10 
7.89 
8.38 * 
7.8 
8.07 
7.95 
0.17 
0.02 
0.32 
0.3 
0.34 
7.84 
7.74 
7.88 
7.82 
7.62 
0.27 
0.3 
0.19 
0.19 
0.18 
6.44 
6.45 
6.25 
5.88 
5.87 
0.51 
0.40 
0.94 
0.85 
0.15 
8.35 
8.89  a 
8.76 
8.56 
8.69 
0.29 
0.083 
0.26 
0.08 
0.29 
GUM 0h 
GUM 5h 
GUM 10h 
GUM 24h 
GUM 48h 
7.33 
7.78  ** 
7.98  * 
7.93 
7.69 
0.05 
0.06 
0.13 
0.28 
0.149 
7.38 
7.32 
7.6 
7.67 
7.34 
0.14 
0.13 
0.31 
0.27 
0.12 
7.58 
7.67 
7.70 
7.66 
7.78 
0.18 
0.29 
0.25 
0.26 
0.27 
7.73 
8.01 ** 
8.21 
8.17 
8.2 
0.22 
0.23 
0.54 
0.3 
0.25 
7.77 
7.6 
7.58 
7.68 
7.46 
0.2 
0.16 
0.2 
0.29 
0.3 
6.39 
6.31 
6.09 
6.57 
6.04 
0.58 
0.67 
0.75 
0.73 
0.91 
8.11 
8.44 
8.74 
8.72 
8.66  * 
0.17 
0.16 
0.47 
0.18 
0.17 
Table  3-b: changes in the bacterial composition figures are presenting the mean bacterial populations in pH-controlled batch cultures at 0, 5, 10, 24, 
and 48h.Values are mean ± SD.*, significant differences  from the 0 h value within the same treatment, p<0.05. small letters differences from the 
negative control. 1% faecal batch culture inoculated with vessel 1 negative control, vessel 2 FOS 1%, vessel 3 FOS 2%, vessel 4 GA 1%, vessel 5 GA 
2%. 
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 618 
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 620 
 621 
 ACETATE PROPIONATE BUTYRATE 
Control 
0 h 1.68 ± 1.16 0.19± 0.12 0.15 ± 0.09 
5 h 4.49 ± 0.99 a 0.82 ± 0.86 2.15 ± 3.19 
10 h 6.47 ± 1.34 2.51 ± 1.19 a 1.47 ± 0.35 
24 h 8.88 ± 1.71 4.50 ± 2.29 1.73± 0.85 a 
48 h 10.57 ± 3.57 5.40 ± 3.11 3.10 ± 2.41 
FOS 1% 
0 h 0.98 ± 0.04 0.10 ± 0.03 0.08 ± 0.02 
5 h 8.84 ± 3.53 ** a 1.86 ± 0.31 0.66 ± 0.24 
10 h 13.12 ± 2.02 ** 8.45 ± 6.98 4.42 ± 2.02 
24 h 11.89 ± 4.22 * 8.13 ± 2.10 * 8.26 ± 2.98 * 
48 h 10.00 ± 1.11 ** 4.32 ± 3.42 1.21 ± 1.58 
FOS 2% 
0 h 1.35 ± 0.26 0.19 ± 0.10 0.13 ± 0.06 
5 h 14.28 ± 4.93 4.24 ± 3.54 2.32 ± 2.10 
10 h 15.08± 2.93 5.80 ± 1.04 * a 5.93± 4.34 
24 h 13.00 ± 7.81 ** 5.44 ± 2.56 6.21 ± 4.05 
48 h 8.80 ± 0.32 * 2.31 ± 1.85 3.66± 1.52 
GUM 1% 
0 h 2.01 ± 1.73 0.18± 0.10 0.16 ± 0.12 
5 h 5.36 ± 0.37 4.79 ± 4.76 4.99 ± 7.61 
10 h 12.72± 4.79 6.77 ± 4.78 6.96 ± 7.79 
24 h 10.78 ± 8.27 3.28 ± 2.61 4.59 ± 1.49 * a 
48 h 11.64 ± 4.10 * 4.79 ± 1.46 * 4.01 ± 0.88 * 
GUM 2% 
0 h 2.37 ± 2.29 0.19±0.12 0.16 ± 0.12 
5 h 5.24 ± 0.56 5.13 ± 5.93 0.73 ± 0.42 
10 h 16.67 ± 7.59 12.03 ± 8.32 2.40 ± 0.51 
24 h 11.41 ± 9.15 3.28 ± 2.51 3.09 ± 2.49 * 
48 h 13.63 ± 3.17 * 6.15 ± 2.24 6.24± 2.22 * 
 622 
 623 
Table 4:  changes in the SCFA concentration are presenting in table 3 in pH-controlled batch 
cultures at 0, 5, 10, 24, and 48h.Values are mean ± SD.*, significant differences from the 0 h 
value within the same treatment, p<0.05. small letters differences from the negative control. 1% 
faecal batch culture inoculated with vessel 1 negative control, vessel 2 FOS 1%, vessel 3 FOS 
2%, vessel 4 GA 1%, vessel 5 GA 2%. 
 
